EGFR and non-small cell lung carcinoma: Gefitinib (GEF), a hydrophobic tyrosine kinase inhibitor, disrupts cancer cell signalling and proliferation through epidermal growth factor receptor (EGFR) binding [6], warranting its approval for the treatment of non-small cell lung cancer with specific EGFR gene mutations [7].